Actinium Pharmaceuticals, Inc. ATNM.OB is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium and bismuth and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company s lead radiopharmaceutical Iomab TM B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase clinical study of Iomab B in refractory and relapsed Acute Myeloid Leukemia AML patients over the age of with a primary endpoint of durable complete remission. The company s second program, Actimab A, is continuing its clinical development in a Phase / trial for newly diagnosed AML patients over the age of in a single arm multicenter trial.
Quote | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
Last: | $7.82 |
---|---|
Change Percent: | -0.76% |
Open: | $7.96 |
Close: | $7.82 |
High: | $8.08 |
Low: | $7.71 |
Volume: | 429,296 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
2024-07-25 10:29:32 ET More on Actinium Pharmaceuticals Actinium Pharmaceuticals: Oversold Despite No Bad News A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies Seeking Alpha’s Quant Rating on Actinium Pharmaceuticals...
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University PR Newswire - Sickle cell disease affects approximately 100,000 patients in the U...
Message Board Posts | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
Subject | By | Source | When |
---|---|---|---|
Been watching the share price and have to | timberwolf7 | investorshub | 04/11/2023 4:24:43 AM |
whytestocks: $ATNM News Article - Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Po | whytestocks | investorshangout | 02/27/2023 1:05:46 PM |
Results were definitely FDA approvable. Everyone is | Pharmboy46 | investorshub | 02/22/2023 6:38:21 PM |
What's wrong? I don't understand! Down 5$ in | blukky | investorshub | 02/22/2023 6:26:34 PM |
PUMP & DUMP | Lonewolf1 | investorshub | 02/21/2023 9:41:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
Actinium Pharmaceuticals Inc. Website:
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University PR Newswire - Sickle cell disease affects approximately 100,000 patients in the U...
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US PR Newswire Presentation to highlight positive outcomes of Iomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for ...